Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/43724
Title: Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in haematological malignancies.
Authors: Al-Zebeeby, A
Vogler, M
Milani, M
Richards, C
Alotibi, A
Greaves, G
Dyer, MJS
Cohen, GM
Varadarajan, S
First Published: 22-Nov-2018
Publisher: Ferrata Storti Foundation with European Hematology Association
Citation: Haematologica, 2018
Abstract: BH3 mimetics are novel targeted drugs with remarkable specificity and potency and enormous potential to improve cancer therapy. However, acquired resistance is an emerging problem. We report the rapid development of resistance in chronic lymphocytic leukemia cells isolated from patients exposed to increasing doses of Navitoclax (ABT-263), a BH3 mimetic. To mimic such rapid development of chemoresistance, we have developed simple resistance models to three different BH3 mimetics, targeting BCL-2 (ABT-199), BCL-XL (A-1331852) or MCL-1 (A-1210477), in relevant haematological cancer cell lines. In these models, resistance could be attributed neither to consistent changes in expression levels of the anti-apoptotic proteins nor interactions among different pro- and anti-apoptotic BCL-2 family members. Using genetic silencing, pharmacological inhibition and metabolic supplementation, we report that targeting of glutamine uptake and its downstream signalling pathways, namely glutaminolysis, reductive carboxylation, lipogenesis, cholesterogenesis and mTOR signalling result in marked sensitisation of the chemoresistant cells to BH3 mimetic-mediated apoptosis. Furthermore, our findings highlight the possibility of repurposing widely used drugs, such as statins, to target intermediary metabolism and improve the efficacy of BH3 mimetic therapy.
DOI Link: 10.3324/haematol.2018.204701
eISSN: 1592-8721
Links: http://www.haematologica.org/content/early/2018/11/19/haematol.2018.204701
http://hdl.handle.net/2381/43724
Version: Post-print
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © 2018, Ferrata Storti Foundation with European Hematology Association. Deposited with reference to the publisher’s open access archiving policy. (http://www.rioxx.net/licenses/all-rights-reserved)
Appears in Collections:Published Articles, Dept. of Cancer Studies and Molecular Medicine

Files in This Item:
File Description SizeFormat 
haematol.2018.204701.full.pdfPost-review (final submitted author manuscript)2.95 MBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.